742112--2/27/2009--INVACARE_CORP

related topics
{regulation, government, change}
{operation, international, foreign}
{product, liability, claim}
{cost, regulation, environmental}
{property, intellectual, protect}
{loss, insurance, financial}
{product, market, service}
{condition, economic, financial}
{competitive, industry, competition}
{system, service, information}
{financial, litigation, operation}
{provision, law, control}
{personnel, key, retain}
{acquisition, growth, future}
{stock, price, operating}
{cost, operation, labor}
{product, candidate, development}
Changes in government and other third-party payor reimbursement levels and practices have negatively impacted and could continue to negatively impact the company s revenues and profitability. The consolidation of health care customers and the company s competitors could result in a loss of customers or in additional competitive pricing pressures. The company is subject to risks arising out of the current global economic and credit crisis. The company s reported results may be adversely affected by increases in reserves for uncollectible accounts receivable. The industry in which the company operates is highly competitive and some of the company s competitors may be larger and may have greater financial resources than the company does. If the company s cost reduction efforts are ineffective, the company s revenues and profitability could be negatively impacted. The company s success depends on the company s ability to design, manufacture, distribute and achieve market acceptance of new products with higher functionality and lower costs. The company is subject to extensive government regulation, and if the company fails to comply with applicable laws or regulations, the company could suffer severe criminal or civil sanctions or be required to make significant changes to the company s operations that could have a material adverse effect on the company s results of operations. The company s research and development and manufacturing processes are subject to federal, state, local and foreign environmental requirements. Lower cost imports could negatively impact the company s profitability. The company s failure to comply with regulatory requirements or receive regulatory clearance or approval for the company s products or operations in the United States or abroad could adversely affect the company s business. The company s products are subject to recalls, which could harm the company s reputation and business. Difficulties in implementing an Enterprise Resource Planning system have disrupted the company s business. The company may be adversely affected by legal actions or regulatory proceedings. Product liability claims may harm the company s business, particularly if the number of claims increases significantly or the company s product liability insurance proves inadequate. If the company s patents and other intellectual property rights do not adequately protect the company s products, the company may lose market share to its competitors and may not be able to operate the company s business profitably. The company s operating results and financial condition could be adversely affected if the company becomes involved in litigation regarding its patents or other intellectual property rights. The company s business strategy relies on certain assumptions concerning demographic trends that impact the market for its products. If these assumptions prove to be incorrect, demand for the company s products may be lower than expected. The loss of the services of the company s key management and personnel could adversely affect its ability to operate the company s business. The company s Chief Executive Officer and certain members of management own shares representing a substantial percentage of the company s voting power and their interests may differ from other shareholders. Decreased availability or increased costs of raw materials could increase the company s costs of producing its products. Since the company s ability to obtain further financing may be limited, the company may be unable to acquire strategic acquisition candidates. The company is subject to certain risks inherent in managing and operating businesses in many different foreign jurisdictions. The company s revenues and profits are subject to exchange rate fluctuations that could adversely affect its results of operations or financial position. Certain provisions of the company s debt agreements, its charter documents, its shareholder rights plan and Ohio law could delay or prevent the sale of the company.

Full 10-K form ▸

related documents
742112--3/1/2007--INVACARE_CORP
1136869--2/28/2007--ZIMMER_HOLDINGS_INC
94328--4/13/2006--STEWART_&_STEVENSON_SERVICES_INC
10795--11/26/2008--BECTON_DICKINSON_&_CO
1099800--2/26/2010--Edwards_Lifesciences_Corp
10795--11/23/2007--BECTON_DICKINSON_&_CO
76334--8/26/2010--PARKER_HANNIFIN_CORP
799729--9/8/2006--PAREXEL_INTERNATIONAL_CORP
10795--11/30/2006--BECTON_DICKINSON_&_CO
1136869--3/2/2006--ZIMMER_HOLDINGS_INC
313143--5/25/2007--HAEMONETICS_CORP
876167--1/29/2009--PROGRESS_SOFTWARE_CORP_/MA
932696--2/25/2010--INSIGHT_ENTERPRISES_INC
912888--3/16/2010--VITAL_IMAGES_INC
1158833--3/13/2008--LIFE_SCIENCES_RESEARCH_INC
874716--2/19/2010--IDEXX_LABORATORIES_INC_/DE
1065059--2/24/2006--USEC_INC
67887--12/1/2010--MOOG_INC
67887--12/2/2009--MOOG_INC
10795--11/25/2009--BECTON_DICKINSON_&_CO
875045--2/9/2010--BIOGEN_IDEC_INC.
1293243--3/3/2006--PRA_International
10795--11/24/2010--BECTON_DICKINSON_&_CO
862668--10/12/2010--ESCALON_MEDICAL_CORP
875045--2/21/2007--BIOGEN_IDEC_INC
920527--5/20/2009--PSS_WORLD_MEDICAL_INC
856982--3/4/2009--MERIT_MEDICAL_SYSTEMS_INC
1133421--2/9/2010--NORTHROP_GRUMMAN_CORP_/DE/
890634--12/4/2009--ALLIED_HEALTHCARE_INTERNATIONAL_INC
880432--9/28/2009--MISONIX_INC